These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 9177413)

  • 1. Changes in epitopes for thyroid-stimulating antibodies in Graves' disease sera during treatment of hyperthyroidism: therapeutic implications.
    Kim WB; Chung HK; Lee HK; Kohn LD; Tahara K; Cho BY
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1953-9. PubMed ID: 9177413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitopes for thyroid-stimulating antibodies in Graves' sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment.
    Kim WB; Cho BY; Park HY; Lee HK; Kohn LD; Tahara K; Koh CS
    J Clin Endocrinol Metab; 1996 May; 81(5):1758-67. PubMed ID: 8626830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies.
    Chung HK; Kim WB; Park DJ; Kohn LD; Tahara K; Cho BY
    Thyroid; 1999 Apr; 9(4):393-9. PubMed ID: 10319947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitopes for thyroid stimulating and blocking autoantibodies on the extracellular domain of the human thyrotropin receptor.
    Tahara K; Ishikawa N; Yamamoto K; Hirai A; Ito K; Tamura Y; Yoshida S; Saito Y; Kohn LD
    Thyroid; 1997 Dec; 7(6):867-77. PubMed ID: 9459630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease.
    Kim WB; Chung HK; Park YJ; Park DJ; Tahara K; Kohn LD; Cho BY
    Thyroid; 2000 Jul; 10(7):579-86. PubMed ID: 10958310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs.
    Kim TY; Park YJ; Park DJ; Chung HK; Kim WB; Kohn LD; Cho BY
    J Clin Endocrinol Metab; 2003 Jan; 88(1):117-24. PubMed ID: 12519839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor.
    Di Cerbo A; Di Paola R; Menzaghi C; De Filippis V; Tahara K; Corda D; Kohn LD
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3283-92. PubMed ID: 10487700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtypes of anti-TSH receptor antibodies classified by various assays using CHO cells expressing wild-type or chimeric human TSH receptor.
    Watanabe Y; Tahara K; Hirai A; Tada H; Kohn LD; Amino N
    Thyroid; 1997 Feb; 7(1):13-9. PubMed ID: 9086564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The formation of thyrotropin receptor (TSHR) antibodies in a Graves' animal model requires the N-terminal segment of the TSHR extracellular domain.
    Kikuoka S; Shimojo N; Yamaguchi KI; Watanabe Y; Hoshioka A; Hirai A; Saito Y; Tahara K; Kohn LD; Maruyama N; Kohno Y; Niimi H
    Endocrinology; 1998 Apr; 139(4):1891-8. PubMed ID: 9528975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of monoclonal thyroid-stimulating and thyrotropin binding-inhibiting autoantibodies from a Hashimoto's patient whose children had intrauterine and neonatal thyroid disease.
    Kohn LD; Suzuki K; Hoffman WH; Tombaccini D; Marcocci C; Shimojo N; Watanabe Y; Amino N; Cho BY; Kohno Y; Hirai A; Tahara K
    J Clin Endocrinol Metab; 1997 Dec; 82(12):3998-4009. PubMed ID: 9398703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.
    Kim WB; Chung HK; Park YJ; Park DJ; Lee HK; Cho BY
    Korean J Intern Med; 2001 Sep; 16(3):187-200. PubMed ID: 11769578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of thyroid-stimulating blocking antibodies that appeared during transient hypothyroidism after radioactive iodine therapy.
    Kung AW; Lau KS; Kohn LD
    Thyroid; 2000 Oct; 10(10):909-17. PubMed ID: 11081257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
    Kung AW; Lau KS; Kohn LD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyrotropin receptor epitopes recognized by graves' autoantibodies developing under immunosuppressive therapy.
    Wortsman J; McConnachie P; Tahara K; Kohn LD
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2302-8. PubMed ID: 9661599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyrotropin receptor autoantibodies (TSHRAbs): epitopes, origins and clinical significance.
    Kohn LD; Harii N
    Autoimmunity; 2003; 36(6-7):331-7. PubMed ID: 14669940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of TSH receptor antibodies in thyroid diseases.
    Cho BY
    J Korean Med Sci; 2002 Jun; 17(3):293-301. PubMed ID: 12068130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors.
    Grasso YZ; Kim MR; Faiman C; Kohn LD; Tahara K; Gupta MK
    Thyroid; 1999 Jun; 9(6):531-7. PubMed ID: 10411114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of recombinant monoclonal antithyrotropin receptor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease: epitope and binding study of two stimulatory TSHRAbs.
    Akamizu T; Moriyama K; Miura M; Saijo M; Matsuda F; Nakao K
    Endocrinology; 1999 Apr; 140(4):1594-601. PubMed ID: 10098493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells.
    Kamijo K; Murayama H; Uzu T; Togashi K; Kahaly GJ
    Thyroid; 2010 Aug; 20(8):851-6. PubMed ID: 20615137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.